India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has entered into a memorandum of understanding with MediCann Handels GmbH for the import and distribution of IGC’s cannabinoid-based therapies to pharmacies in Germany. Under the terms of the MOU, MediCann will provide the capital required for the transportation, import, storage, sales and marketing of products intended for the German market. “There are many benefits to developing a strong presence in the German pharmacy market including, a favorable regulatory environment and reimbursement from health insurance providers,” Ram Mukunda, CEO of IGC, stated in the news release. “The agreement with MediCann is the first step in the commercialization process of our therapies, as we work out the logistics of how to efficiently deliver our products to Germany.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
India Globalization Capital, Inc. (NYSE: IGC) Enters MOU Related to Import and Distribution of Cannabinoid-Based Therapies in Germany
